Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on FibroGen (FGEN – Research Report), BioNTech SE (BNTX – Research Report) and Sensei Biotherapeutics (SNSE – Research Report).
FibroGen (FGEN)
Goldman Sachs analyst Paul Choi maintained a Sell rating on FibroGen yesterday and set a price target of $2.00. The company’s shares closed last Monday at $0.56, close to its 52-week low of $0.47.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
FibroGen has an analyst consensus of Moderate Sell, with a price target consensus of $2.00.
See today’s best-performing stocks on TipRanks >>
BioNTech SE (BNTX)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE, with a price target of $159.00. The company’s shares closed last Monday at $99.71, close to its 52-week low of $88.00.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $130.83, implying a 29.2% upside from current levels. In a report issued on October 23, Canaccord Genuity also maintained a Buy rating on the stock with a $184.00 price target.
Sensei Biotherapeutics (SNSE)
In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Sensei Biotherapeutics, with a price target of $6.00. The company’s shares closed last Monday at $0.76.
According to TipRanks.com, Semenkow is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Sensei Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FGEN:
